Welcome to article directory Cancer from Asbestos. Here You can find interesting and useful information on most popular themes.

There are 592 published articles and 1 registered authors in our article directory.

Recent Articles

Multaq Proclamation

By admin | Published January 25, 2012

Multaq : Imaging Studies

Usually the doctor will want to obtain at least one imaging study (usually a sono­gram) at some point during the diagnostic evaluation of chronic hepatitis B, especially when LFTs are elevated. While an enlarged liver or spleen may be detected on occasion, in general, imaging studies are usually normal—even in advanced stages of the disease. If liver cancer (hepatoma) is present, a mass may be revealed. See chapter 19 for more information on liver tumors. However, just because the liver looks normal on an imaging study does not mean that the liver is normal. That is why a liver biopsy is necessary when more information about the condition of the liver is needed.

More information on Multaq

The Different Types of Chronic Hepatitis B

People with chronic hepatitis B may be divided into three categories: (1) inactive hepatitis B surface antigen (HBsAg) carrier state; (2) chronic hepatitis B, which is divided into HbeAg positive and HBeAg negative chronic hepatitis B; and (3) re­solved chronic hepatitis B. Everyone with chronic hepatitis B is, by definition, both HBsAg and HBcAb positive. (Refer to table 9.1 on page 100 for a discus­sion of these and some related terms.) This means that both the hepatitis B sur­face antigen and core antibody are detectable in their blood.

Inactive HBsAg Corner Stote

The first type of chronic hepatitis B is found in a person who carries hepatitis B, is HBsAg and HBcAb positive, but who has normal liver enzymes (AST and ALT), a normal physical exam, and is asymptomatic. Such a person is referred to as an in­active carrier of hepatitis B. HBeAg and HBV DNA are negative, and HBeAb is typically positive—indicating that this person is not infectious to others. Inactive carriers of HBV usually have minimal, if any, liver inflammation or damage. They usually live a normal life without any complications due to their liver disease. However, compared with the genera! population, these people are at a somewhat higher risk for cirrhosis and liver cancer. Therefore, regular observation—in the form of visits to the doctor approximately one to two times per year for a physical exam and blood tests—is necessary to check for early signs of disease progression.

 

Information from other sources on Multaq

Liver Biopsy

As with all liver diseases, even if a person feels Fine, that’s no guarantee that her liver is fine. The only way to determine the degree to which one’s liver is injured is by examining a sample of the liver under a microscope. Therefore, in addition to ob­taining a battery of blood tests, including LFTs and the hepatitis B serology, the doctor will need to perform a liver biopsy to determine the full extent of damage done to the liver by the virus and to determine if treatment is necessary. A liver

 

biopsy is the only reliable means of determining the presence or absence of cir­rhosis. Some studies have demonstrated that the results of a liver biopsy per­formed promptly after diagnosis can predict the future course of disease.

Our use of the term or terms Multaq is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq visit our site often.

http://www.seedol.com

Posted in Cancer from Asbestos | Tagged , |

Multaq Lawsuit Breaking News

By admin | Published January 25, 2012

Multaq Lawsuit : Chronic Hepatitis B and Long-term Liver Cancer Risk

People with chronic hepatitis B are at increased risk for developing liver cancer. The exact risk is unknown, but in some studies, people with chronic hepatitis B were two hundred times more likely to develop liver cancer compared with people without this disease. Cancer usually occurs in those who have developed cirrhosis. However, cancer can also occur in chronic HBV carriers without cir­rhosis. In fact, in some parts of the world where hepatitis B is endemic, such as in Africa, up to 30 percent of people with chronic hepatitis B develop liver can­cer without underlying cirrhosis.

Prom the time a person becomes infected with HBV, liver cancer generally takes about twenty to thirty years to develop. Thus, people who were infected at birth can develop liver cancer as early as the age of twenty. It appears that infec­tion with both HBV and HCV or infection with both HBV and HDV, drinking ex­cessive alcohol, and having a family history of HCC can increase the likelihood that a person will develop liver cancer. It has been noted that men appear to have an increased risk ot developing HCC compared to women. Whether this is due to hormonal differences is unclear. See chapter 19 for more information on HBV and liver cancer.

More information on Multaq Lawsuit

THE HEPATITIS DELTA VIRUS (HDV)

Hepatitis D is inflammation of the liver due to a virus called the hepatitis delta virus (HDV). HDV is a virus that can live only in people with hepatitis B. Ap­proximately 70,000 people in the United States are infected with HDV. Although HDV only accounts for a small percentage of cases of chronic viral hepatitis, it tends to be particularly severe and to have significant long-term consequences. In fact, chronic hepatitis D causes more than one thousand deaths each year in the United States. In the 1970s, hepatitis delta virus infection was endemic through­out Southern Europe. However, by the 1990s the incidence of HDV infection had significantly decreased. In fact, one study done in Italy estimated that the num­ber of cases of HDV within that country decreased by 1.5 percent each year from 1987 to 1997. And, it is anticipated that this trend will continue. Currently, new HDV infections are rare.

Information from other sources on Multaq Lawsuit

HDV infection may be silent or may cause the same kind of fatigue and other symptoms associated with other forms of hepatitis. However, up to 20 percent of hepatitis D patients develop fulminant hepatitis, a particularly serious condition that requires hospitalization. See chapter 7 for a discussion on fulminant hepatitis.

HDV is transmitted through the same blood, sexual, and perinatal routes as HBV, which were discussed on page 92. There are two ways in which a person infected with HBV may become infected with HDV: coinfection and superinfection. When HBV and HDV are acquired at the same time, it is known as coinfection. In 90 to 95 percent of cases, such people will be able to completely eliminate both viruses from their bodies. This means that only approximately 5 to 10 percent of coinfected individuals go on to develop chronic hepatitis B and D. HDV can also be acquired by someone who already has chronic hepatitis B. This is known as superinfection. In contrast to people infected with both viruses simultaneously, approximately 70 to 95 percent of people who become infected in this two-step fashion progress to chronic hepatitis D.

Our use of the term or terms Multaq Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Lawsuit visit our site often.

http://www.seedol.com

Posted in Cancer from Asbestos | Tagged , |

Yaz Lawsuit News

By admin | Published January 25, 2012

Yaz Lawsuit News 1/23/2012: Until recently, it had appeared self-evident that (nonembolic) arterial thrombosis was the culmination of slow enlargement of the mature atherosclerotic lesion with progressive encroachment into the arterial lumen. This pathobiological construct supported the view that the risk of acute thrombosis was dominated by the sever­ity of arterial stenosis. However, over the past decade, angiographic and patholog­ical data obtained in the coronary arterial bed have challenged this construct. Angiography performed prior to or at the time of acute myocardial infarction has demonstrated that the infarct-related coronary atherosclerotic lesion is frequently not ‘‘critical’’ by standard angiographic criteria. Similarly, pathological examination of culprit lesions has demonstrated that the majority of acute coro­nary events occur with the formation of thrombus at the site of plaques obstruct­ing <50% of the arterial lumen. Taken together with evidence for the impor­tance of plaque disruption in the development of superimposed thrombus (56,65­69), such data have shifted focus from the degree of luminal stenosis to the mor­phological and histological characteristics of the atheromatous plaque that deter­mine its propensity to rupture.

Lending further support to the contribution of inflammatory mechanisms to plaque destabilization, onset of acute thrombosis with or without myocardial necrosis is marked by the production of a number of inflammatory cytokines. In addition, a series of studies have suggested a link between the elabo­ration of inflammatory cytokines and impairment of the ability of smooth muscle cells to maintain the integrity of the fibrous cap (52). Interferon-gamma (IFN-y), a cytokine produced by T-lymphocytes within the atheroma core, decreases the production of collagen by vascular smooth muscle cells (80-82). Smooth muscle cells at the site of plaque rupture or erosion have been found to express high levels of the transplant antigen HLA-DRa, a protein induced only by IFN-y among a wide spectrum of cytokines evaluated

More information on Yaz Lawsuit:

Vascular inflammation may also influence arterial vasomotor function through several possible mechanisms. Increased concentrations of thromboxane A2 and its metabolites produced in acute coronary syndromes (99,100) mediate further platelet aggregation as well as arterial vasoconstriction (101). Leukocytes also produce en- dothelin-1, a potent modulator of vasoconstriction. In addition, certain inflammatory cytokines may increase vascular smooth muscle cell reactivity, as demonstrated in an animal model with IL-1 (102). Finally, inflammatory infiltrates have been documented in the arterial adventitia with vascular nerve involvement and thus have been hypothesized to directly stimulate coronary vasospasm.

In spite of continued advancements in the management of acute ischemic heart disease, morbidity and mortality due to atherosclerotic vascular disease continue to rise globally. Thus, the impetus for improving our strategies for the prevention and management of atherosclerosis has remained strong. In this re­gard, laboratory and experimental research describing key processes in the initia­tion, progression, and destabilization of the atheroma have pointed to novel direc­tions for cardiovascular evaluation and management. In particular, recognition of the role of inflammation in atherothrombosis has directed attention to inflam­matory mediators and indicators as potential targets for risk assessment and for treatment.

Information from other sources on Yaz Lawsuit:

Epidemiological data have established a well-characterized set of vascular risk factors, including advanced age, tobacco use, obesity, diabetes, hypertension, and dyslipidemia. However, up to one-third of first coronary events occur among individuals without these traditional risk factors. Researchers have thus sought to identify inflammatory indicators that might add to these clinical factors for predicting myocardial infarction and stroke. Candidate markers have included several of the cytokines (77,108,109) that promote the recruitment of monocytes in response to endothelial cell dysfunction; intercellular adhesion mol­ecules that mediate the migration of activated monocytes into the subendothelial space; enzymes that might compromise the integrity of the protective fibrous cap, as well as the acute-phase proteins that are produced and released into the systemic circulation in response to inflammatory cytokines.

With systemic levels that are dependent on the rate of de novo hepatic production, CRP levels remain stable over long periods of time in the absence of new stimuli. However, in response to acute tissue injury, infection, or other inflammatory stimuli, CRP levels rise several hundred-fold. As such, CRP and its acute-phase counterpart, serum amyloid A, have been useful in fol­lowing disease activity in chronic inflammatory conditions such as systemic lu­pus, inflammatory bowel disease, and rheumatoid arthritis. Traditional semiquantitative latex agglutination or standard turbidometric methods have been adequate to evaluate such marked elevation of CRP in these disease processes. In contrast, the development of high-sensitivity assays for CRP (hs-CRP) has now enabled detection of CRP within the normal range for healthy individuals. Further, the introduction of high through-put methods with high ana­lytical sensitivity and reproducibility has provided a simple clinical tool to care­fully evaluate the extent of underlying systemic inflammation.

Yaz Lawsuit: More information from other sources related to your search

Antiphospholipid antibodies (APLA) are a heterogeneous group of autoantibod­ies associated with both arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. They can occur either in association with other auto­immune conditions, most frequently systemic lupus erythematosus (SLE), or in isolation, a condition known as the primary antiphospholipid antibody syndrome. In the research laboratory, many antiphospholipid antibodies (with varying epi­tope specificity) can be identified. However, in clinical practice, the antiphospho­lipid antibodies are divided into two large groups, the lupus anticoagulants and the anticardiolipin antibodies.

Lupus anticoagulants or nonspecific inhibitors interfere with the assembly of procoagulant complexes. In vitro, these antibodies are associated with the pro­longation of phospholipid-dependent blood-clotting times. Characteristically, clotting times return to normal with the addition of exogenous phospholipid. Lu­pus anticoagulants may demonstrate specificity for blood-clotting proteins, in particular prothrombin. However, the mechanism by which they promote throm­bosis is unknown. Lupus anticoagulants are likely associated with a high risk of first and recurrent thrombosis as well as recurrent pregnancy loss.

Yaz Lawsuit: Additional News and Information about Yaz Lawsuit:

APLA are found in about 20% of patients presenting with venous thromboembo­lism (1,2), in about 10% of patients presenting with first ischemic stroke (3), and in approximately 5 to 10% of young people presenting with first myocardial infarction (4). Their prevalence in the unselected population is unknown; reported rates vary widely with the test system used and the population being studied. About 30% of individuals with systemic lupus erythematosus have an APLA (5). Low-titer anticardiolipin antibodies are frequently detected in otherwise well individuals; repeat testing reveals a high rate of spontaneous resolution.

All patients with unexplained venous thrombosis, in particular those with thrombosis in unusual sites (such as the cerebral veins or mesenteric veins), should be screened for an antiphospholipid antibody. Both a lupus and an anticar- diolipin antibody should be sought. Testing should be carried out in accordance with the recommendations of the International Society of Thrombosis and He- mostasis, with appropriate confirmatory assays for suspected lupus anticoagu­lants.

Many questions remain unanswered in patients with antiphospholipid antibodies. First, many patients, particularly those with systemic lupus erythematosus, are screened for the presence of an antiphospholipid antibody despite their never having had an episode of thrombosis. When detected, the clinical importance of the antibody is unknown. As a result, some such patients (who are suspected to have a high risk of first thrombosis) are treated with warfarin with varying INR target ranges, while others are treated with aspirin or other antiplatelet agents, and many receive no antithrombotic prophylaxis. To address the need for routine antithrombotic prophylaxis in this problematic patient population, a large, ran­domized clinical trial is currently being carried out. Within this study, adults and children, with both an antiphospholipid antibody and systemic lupus erythemato­sus, are allocated to long-term warfarin with a target INR of 2.0, or no therapy. The primary outcome measure of the study is the rate of objectively confirmed arterial and venous thrombosis.

Our use of the term or terms Yaz Lawsuit: is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Yaz Lawsuit :visit our site often.

http://www.seedol.com

Posted in Cancer from Asbestos | Tagged , |

Vaginal Lawsuit Petition

By admin | Published January 25, 2012

Vaginal Lawsuit : Oestrogen receptors have been demonstrated in the squamous epithelium of both the proximal and distal urethra.24 Oestrogen has been shown to improve the maturation index of urethral squamous epitheLium.25It has been suggested that oestrogen increases urethral closure pressure and improves pressure transmission to the proximal urethra, both of which promote continence. Epidemiological studies have implicated oestrogen deficiency in the aetiology of lower urinary tract symptoms. Seventy percent of women relate the onset of urinary incontinence to their final menstrual period.2 Lower urinary tract symptoms have been shown to be common in postmenopausal women attending a menopause clinic, with 20% complaining of severe urgency and almost 50% complaining of stress incontinence.

There is, however, conflicting evidence regarding the role of oestrogen withdrawal at the time of the menopause. Some studies have shown a peak incidence in perimenopausal women36‘37 whilst other evidence suggests that many women develop incontinence at least 10 years prior to the cessation of menstruation, with significantly more premenopausal women than postmenopausal women being affected.

For more information on Vaginal Lawsuit follow us on our RSS Feeds.

Urinary tract infection is also a common cause of urinary symptoms in women of all ages. This is a particular problem in the elderly with a reported incidence of 20% in the community and over 50% in institutionalized patients.39‘40 Pathophysiological changes, such as impairment of bladder emptying, poor perineal hygiene and both faecal and urinary incontinence, may partly account for the high prevalence observed. In addition, as previously described, changes in the vaginal flora due to oestrogen depletion lead to colonization with Gramnegative bacilli, which, as well as causing local irritative symptoms, also act as uropathogens. These microbiological changes may be reversed with oestrogen replacement following the menopause, offering a rationale for treatment and prophylaxis.

Information from other sources on Vaginal Lawsuit

Oestrogen preparations have been used for many years in the treatment of urinary incontinence,41‘42 although their precise role remains controversial. Many of the studies performed have been uncontrolled observational series examining the use of a wide range of different preparations, doses and routes of administration. The inconsistent use of progestogens to provide endometrial protection is a further confounding factor making interpretation of the results difficult.

Our use of the term or terms Vaginal Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Vaginal Lawsuit visit our site often.

.

Posted in Cancer from Asbestos | Tagged , |

Trans Vaginal Mesh Lawsuit Data

By admin | Published January 25, 2012

Trans Vaginal Mesh Lawsuit : Fistulae are rare in England and are usually secondary to gynaecological surgery, maLignancy or radiotherapy. A fistula is an abnormal connection between two epithelial surfaces. Surgical procedures associated with vesicovaginal fistula. Obstetric fistulae are much commoner in the developing world and are a frequent reason why women are cast out of their homes and communities and abandoned. Urethrovaginal and ureterovaginal fistulae are much less common than vesicovaginal fistulae. In the developed world they are unusual causes of urinary incontinence (UI). Once again, the most common cause of these fistuale in the developing world is obstetric trauma due to ischaemic necrosis; in developed countries the most common cause is surgery. Anterior repair, vaginal hysterectomy and urethral diverticulectomy have all been associated with an increased risk of urethral fistula formation.

USI, as opposed to the patient symptom ‘stress urinary incontinence’ (SUI), is only diagnosed after performing urodynamics and is the involuntary leakage of urine per urethram during periods of raised intraabdominal pressure, in the absence of a detrusor contraction. Normal urethral function maintains a positive urethral closure pressure in the presence of raised intraabdominal pressure, although DO may overcome it. An incompetent urethra allows leakage of urine, even in the absence of a detrusor contraction. Damage to the pubo- urethral ligaments and the levator ani muscles (secondary to pregnancy, childbirth, obesity, radical pelvic surgery, abdominopelvic mass or chronic cough, and possibly exacerbated by inherited weak collagen) may allow bladder- neck hypermobility and descent of the bladder neck and proximal urethra, so that they are no Longer within the intraabdominal pressure zone.

For more information on Trans Vaginal Mesh Lawsuit follow us on our RSS Feeds.

demonstrated denervation of the intrinsic and extrinsic sphincter mechanisms.5,6This is known as ‘intrinsic sphincter deficiency’, where the hermetic closure properties of the proximal urethra are lost and USI may be the result. From September 2004 the first drug treatment for SUI, duloxetine, will be available. It is essential to be sure of the diagnosis by excluding DO (see Chapter 6) – a minority of patients opting for a surgical treatment develop irritative symptoms of urgency and frequency or voiding difficulty postoperativeLy, and pre­existing symptoms are likely to be exacerbated.

DO is a urodynamic observation characterized by involuntary detrusor contractions that may be spontaneous or provoked. The contractions occur during the filling phase. Phasic DO is defined by a characteristic waveform that mimics the normal voiding cycle, but which does not inevitably lead to UI. Terminal DO is defined as a single involuntary detrusor contraction at cystometric capacity, which cannot be suppressed, and leads to incontinence – usually complete – and catastrophic bladder emptying.7 Provoked DO is the association of a detrusor contraction with either a physical provocation to the bladder, such as coughing and standing, or a psychological provocation such as hearing running water.

Information from other sources on Trans Vaginal Mesh Lawsuit

Symptomatically, these patients are similar to, and often indistinguishable from, patients with DO. Sometimes, however, low compliance may be associated with a fast bladder-filling rate. Low compliance is seen less often at Patients with DO are often indistinguishable from patients with low compliance; however, low compliance may be associated with a fast bladder-filling rate and is seen less often at physiological filling rates. The incidence of DO increases with age, and urge incontinence is the commonest symptom of incontinence in people aged over 60 years8 and the elderly.9 Urodynamic assessment is required to make an accurate diagnosis, as women usually present with multiple symptoms, most commonly a syndrome of frequency, urgency and nocturia. The pathophysiology of DO is poorly understood and an underlying cause is rarely found, leading to the term idiopathic DO. Detrusor overactivity and USI can coexist as mixed incontinence and DO can arise de novo after incontinence surgery.

Our use of the term or terms Trans Vaginal Mesh Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Trans Vaginal Mesh Lawsuit visit our site often.

Trans Vaginal Mesh Lawsuit

Posted in Cancer from Asbestos | Tagged , |

Mesothelioma Cancer Information

By admin | Published January 25, 2012

Mesothelioma Cancer : After performing the physical exam and taking a his­tory that concentrates on whether you have developed shortness of breath or pain, the doctor will order a chest x-ray. Based on what is found, the doctor will determine what other tests you will need. The doctor may also order blood work. When a tumor or fluid is found, the doctor will need to perform a procedure that mil obtain cells for the physicians to study to determine whether this is a cancer or not. This can be done by performing a biopsy of the mass or by tapping fluid (inserting a needle and drawing out fluid) from the chest or belly cavity and then analyzing the cells that come with the fluid. The analysis of cells from fluid is called cytology. Although an x-ray or scan may provide useful information about the size, shape, and location of a tumor or fluid and may alert your doctor to the possibility of a cancer, an actual diagnosis of mesothelioma cannot be made without a biopsy, or undeniable evidence of cells in the fluid that have the characteristics of a mesothelioma. Mesothelioma Cancer

For more information on Mesothelioma Cancer follow us on our RSS Feeds.

There are no specific blood tests that can tell your doctor you have mesothelioma. Certain blood cell values may be abnormal when a patient has mesothelioma, but these are nonspecific (that is, they do not definitively tell the doctor that it is mesothelioma or another type of cancer or a benign condition). The white blood cell count (cells that fight infection) may be elevated and/or the platelet count (cells that help the clotting system) maybe elevated above normal values.

The liquid part of blood (serum) is partially comprised of dissolved proteins. Currendy, there are no specific proteins in the serum that can tell your doctor you have asbestosis or mesothelioma. Proteins that are spe­cific to a certain disease are called biomarkers. There is great interest in the discovery of these biomarkers, which may represent unique proteins from the tumor that appear early in the disease and increase as the dis­ease progresses. Ask your physician whether any of these markers are under study or whether any have been approved by the FDA for the study of mesothe­lioma. These markers include soluble mesothelin related protein (SMRP) and osteopontin. Mesothelioma Cancer

Information from other sources on Mesothelioma Cancer

The results of the chest x-ray will usually prompt the doctor to order a CAT or CT scan (computerized axial tomography scan) of the chest and abdomen. These scans provide a three-dimensional view of the area of the body that the physician is interested in. CT scans have a better ability to show how much solid mass is present and how much fluid contributes to the picture. They also give a much better anatomic picture so your doctor can see how any masses relate to the lung, heart, diaphragm (the muscle that helps you breathe), and blood vessels in the chest or abdomen. CT scans do not tell the doctor what type of tumor it is or whether the disease has invaded other structures, but they do give a very good idea of whether your disease can be classified as early with minimal disease (Stage I), later with moderate amount of disease (Stage II), or advanced with a large amount of disease (Stages III and IV). (We will discuss the concept of staging in more detail later on.) In mesothelioma, a CT scan is not very good for showing whether your lymph nodes (the round structures in certain positions in the chest and abdomen that drain the lung and intestines and act as filters and sites for immune responses) are involved. The reason it does not show this well is that the pleura can be thickened in areas where the lymph nodes are, and this lumpy, bumpy thickening can be confused with lymph nodes or can hide lymph nodes.

Our use of the term or terms Mesothelioma Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Mesothelioma Cancer visit our site often.

Mesothelioma Cancer

Posted in Cancer from Asbestos | Tagged , |

Actos Cancer Data

By admin | Published January 25, 2012

Actos Cancer: This shift in treatment direction is a very important point and it can be confusing. On the one hand, your medi­cal team is still trying very actively to cure the cancer, if possible, and to prolong your life and improve its quality to the maximum extent. However, because the chance of cure is somewhat smaller, you and your medical team must also give thought to the benefits and drawbacks of treatment, to quality-of-life issues, and to making the decisions that make the most sense. You and your doctors will want to weigh the chance that treatment might be successful against the possible side effects, the time spent in treatment, and the possible limitations on your quality of life.

Your doctor may discover the metastasis during a rou­tine checkup, although sometimes a patient will experience symptoms. It might be bone pain, abdominal discomfort, severe headache, or tingling in the legs. (The latter may occur if a metastasis is pressing on nerves in the spine.) Per­haps you have lost weight without changing exercise or diet habits. A patient might develop a cough or abdominal pain, or experience hematuria (blood in the urine) or other symp­toms of bladder irritation.

For more information on Actos Cancer follow us on our RSS Feeds.

Any of these symptoms should send you to the phone to make an appointment with your doctors. They, in turn, will try to figure out if something sinister is beginning to occur. As you read this you might be thinking that if the cancer is so advanced-—-if it has spread to the lungs or bones—what’s the point of treating symptoms such as tingling in your legs or vague abdominal pain? Doctors take these symptoms seriously because even though the cancer has advanced and metastasized, you are likely to live for an extensive period of time—months or years-—-and it makes good sense to make sure that you are able to live that time as comfortably and as fully as pos­sible. If symptoms go untreated, your ability to participate in everyday life with your family and friends may be greatly diminished, and the time you have left with them may be cut short.

On the other hand, occasionally a specialist may decide to watch and wait. A doctor might make this choice, for example, when a change is seen on an X-ray but the patient is not experiencing any other symptoms. Or when a patient is unwell from other medical problems or is just keen to avoid treatment at that time. In such situations, sometimes the decision will be made to observe closely and start treat­ment when symptoms occur.

Information from other sources on Actos Cancer

What kind of treatment can a patient expect if the can­cer metastasizes? Surgery to remove the bladder is occasion­ally a possibility if the only site of recurrence is the bladder and surrounding tissues. It usually doesn’t make sense to operate if the cancer has spread to distant sites. Sometimes radiotherapy will be used to reduce the symptoms of recurrence in the bladder if the recurrence is too extensive to permit surgery or if distant metastases have also occurred. Chemotherapy is usually used if the cancer has spread widely or to distant sites, and radiotherapy is sometimes used for an isolated metastasis (for example, to the brain or to a bone). A palliative care specialist may be brought in for consultation on how to reduce your pain or make you more comfortable as your disease progresses. And your doctors may talk with you about participating in a clinical trial.

Our use of the term or terms Actos Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Cancer visit our site often.

Actos Cancer

Posted in Cancer from Asbestos | Tagged , |

Actos Side Effects Scoop

By admin | Published January 25, 2012

Actos Side Effects :

WHAT IS THE FUNCTION OF THE BLADDER?

A bladder stores urine and expels it at a convenient time. The bladder is a very useful organ, (tissues working together to accomplish a function), but an individual can live a normal life without one, if required, by surgical creation of a substitute.

 

ARE THERE DIFFERENT TYPES OF BLADDER CANCER?

More than 90% of bladder cancers arise from the lining bladder cells called transitional cells. Bladder cancer is almost always transitional cell cancer. These cells are also present in the urethra (the body tube which drains the bladder), as well as the renal pelvis (inner lining of the kidneys), and the ureters (the body tube draining the kidneys).

Bladder cancer can vary from the non serious, low grade superficial type (approximately 70%), to the invasive, aggressive type that can spread and prove to be fatal (approximately 30%).

5% of bladder cancer is accounted for by squamous cell carcinoma. This cancer is usually secondary to long term inflammation or infection of the bladder. Even rarer is adenocarcinoma, which accounts for less than 2% of all bladder cancers.

HOW COMMON IS BLADDER CANCER?

The American Cancer Society estimates that in 2006,61,420 new cases of bladder cancer were diagnosed in the United States with approximately 73% of those occurring in men. In the same year, this cancer caused approximately 13,060 deaths with approximately two out of three of those being in men. The disease is more common in whites than blacks. The incidence of bladder cancer increases with age in both sexes. When bladder cancer occurs in young people, it tends to grow slower and not be as serious. In men, it is the fourth most common cancer. However, because of the rate of recurrences and long term survival, it is the second most prevalent cancer in middle aged and elderly men. In women, it is the eighth most common cancer. The average age at diagnosis is 65. Over the past decade, there has been both an increased incidence, but also an increased rate of survival for bladder cancer [1]

WHAT CAUSED MY CANCER?

A mutation is a disruption in the DNA of a cell, leading to a loss of regulated cell growth. Mutations can occur spontaneously as we age. It is truly amazing that all of us don’t develop cancer as we are composed of trillions of cells dividing regularly over decades. Fortunately, our cells have repair mechanisms which can often fix damaged cells before cancer arises. In addition, the immune system can destroy cancer cells before they have a chance to grow into tumors.

Mutations and cancer can also be triggered by environmental factors. Certain chemicals have been identified to be particularly effective at inducing mutations in our DNA and subsequent cancer. These chemicals are called carcinogens. Smoking is the most common culprit! Cigarette smoking has a strong link with bladder cancer. Studies have shown approximately 50% of bladder cancer is secondary to tobacco smoke. Smoking releases dozens of carcinogens into the lungs and then into the blood stream. Many of these carcinogens are excreted by the kidneys.

More information on Actos Side Effects

IT IS TOO DIFFICULT TO QUIT SMOKING; IS THERE ANY SURE FIRE WAY TO QUIT?

Tobacco smoke contains nicotine, an extremely addictive chemical. Men overall find it easier to quit smoking than women. When facing the prospects of losing your bladder to cancer or possibly your life, most individuals will become convinced and many simply stop smoking “cold turkey.” Unfortunately, many choose not to quit until their cancer repeatedly recurs or becomes invasive, needlessly placing their health at risk. For those who need assistance in quitting, nicotine patches, gum, and lozenges are all available over the counter. These products allow the smoker to quit without experiencing the discomfort of withdrawal from nicotine. Many smokers also find hypnosis or support groups useful. In addition, prescription medication is available.

ARE THERE ANY OTHER KNOWN CAUSES?

Occupational exposure may account for up to 20% of bladder cancers. Those exposed to aniline dyes (used to color fabrics), aldehydes (used in chemical dyes and in the rubber and textile industries) and those using organic chemicals (used in a wide range of occupations) are all at increased risk. Individuals previously treated with radiation to the pelvis or having received cyclophosphamide (a type of chemotherapy) are at markedly increased risk for developing bladder cancer. If your well water is high in arsenic, your risk may also be increased. Studies have also correlated obesity and a high fat diet, especially with increased cholesterol, as a possible contributing factor.

CAN I HELP TO PREVENT BLADDER CANCER BY DRINKING MORE FLUIDS?

Surprisingly, the answer may be yes. In a recent study, the relationship of diet to cancer was analyzed in a group of47,000 health professionals.[1] In the case of bladder cancer, those who drank the most fluid (greater than 10 cups/day) had half the risk as those who drank the least (less than 5 cups/day). The type of nonalcoholic beverage was less important than the total amount.

WILL MY CHILDREN BE AT HIGHER RISK OF DEVELOPING BLADDER CANCER?

Although there have been clusters of bladder cancer reported, most researchers believe these may be secondary to risk factors such as smoking and exposure to carcinogens. At this time, there is no convincing evidence bladder cancer risk is hereditary. If an environmental factor caused your cancer and your children are exposed as well, their risk of cancer may be increased.

WHAT IS CANCER?

The basic building block of the body is the cell. Cells are specialized to perform a particular function. Skin cells are distinctly different from liver cells which are different from bladder cells. An organ is composed of various cells working in unison to carry out a body function. Cells eventually get old and die. New cells are created by cell division. When cells are behaving normally, they only generate enough new cells to replace the old dying ones. Occasionally, cell growth becomes unchecked. As the cells continue to divide, a tumor (abnormal growth of cells) may form. Such tumors may be benign (no ability to spread beyond their organ of origin) or cancerous (a malignant tumor with the ability to spread beyond their organ of origin and cause harm and possibly death).

Information from other sources on Actos Side Effects

HOW CAN I TELL IF MY BLADDER CANCER IS LIKELY TO SPREAD?

Larger tumors are more likely to spread than smaller tumors. Another critical concern is the grade of the tumor. Normal cells are specialized, differentiated to perform specific function, and have a typical structural arrangement with surrounding cells. As cancers worsen, the cells become less specialized, less differentiated, and lose their normal structural arrangement, resulting in a higher pathologic grade.

In the case of bladder cancer, pathologists classify them into 3 grades based on a number of criteria:

Grade 1: low grade, well differentiated Grade 2: intermediate grade, moderately differentiated Grade 3: high grade, poorly differentiated The higher grade tumors have a greater propensity to metastasize- spread throughout the body.

For bladder cancer, another key indicator for likelihood to spread is the depth of penetration into the bladder wall. The bladder wall is composed of an inner lining called the urothelium (made up of transitional cells) which rests on a membrane layer called the basement membrane, below which is the connective tissue layer (support tissues) called the lamina propria. Within the lamina propria lies a small amount of muscle called the muscularis mucosa. Deep to the lamina propria is the deep muscle of the bladder arranged in three layers. This layer is called the muscularis propria. Tumors located in the inside, superficial layers of the bladder wall are unlikely to spread. Tumors that grow into the deeper layers (down into the muscle of the bladder wall) are much more likely to spread. Furthermore, there is a definite link between the grade of the tumor and its likelihood of invasion. Low grade tumors are almost always noninvasive, while high grade tumors are usually invasive. In general, papillary tumors, which are delicate and frond like in appearance are usually low grade and superficial. This is to be contrasted to sessile tumors which appear solid, are often high grade and invasive. Depth of invasion is critical in establishing prognosis. The tumor which invades into the lamina propria is a far more serious tumor than the superficial tumor which demonstrates no invasion. It has a much higher propensity to progress to the muscle invasive tumor, a much more dangerous cancer, with a high risk for spreading beyond the bladder. For further information see Chapter 6.

 

 

Our use of the term or terms Actos Side Effects is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Side Effects visit our site often.

 

http://www.seedol.com

Posted in Cancer from Asbestos | Tagged , |

Actos and Bladder Cancer Scoop

By admin | Published January 25, 2012

Actos and Bladder Cancer: For the practicing urologist it is often difficult to inform the patient on muscle invasive bladder cancer and the often need for radical surgery and some kind of urinary diversion to follow; however, it is even more elaborate to do so in case of a nonmuscle invasive tumor where the evidence calls for radical treatment. In Chap. 15, Waalkes, Merseburger, and Kuczyk present pathologies where a radical treat­ment is strongly advised.In Chapters 16-18 focus various aspects of cystectomy. In Chap. 16, radical surgery of the bladder is discussed by Dr. Gschwend. The improvement in surgical techniques had led this formerly challenging procedure into a more standardized one. Chapter 17 includes urinary diversion by Drs. Richard and Stefan Hautmann. The ileal neobladder has become one of the worldwide chosen procedures for con­tinent orthotopic urinary diversion. Chapter 18, laparoscopic cystectomy by Dr. John, is the latest evolvement in bladder surgery and covers innovative tech­niques as well as the well-established surgical routines in radical treatment of invasive bladder cancer.

 

More information on Actos and Bladder Cancer

In 2010, only 5% of all urologists are performing neoadjuvant chemotherapy in patients with muscle invasive bladder cancer, hence the 5% survival benefit in5 years and possible down staging of the tumor. Dr. Sherif guides us along the current literature and discusses the pros and cons of the neoadjuvant chemotherapy. Diagnosis and treatment of upper tract tumors is challenging and Chap. 20 by Dr. Remzi discusses the basics as well as recent advances in this field. In Chap. 21, De Santis and Bachner focus on the development and optimal use of new regimens for systemic agents as well as standard treatment options for the treatment of meta­static urinary carcinoma in the areas of targeted drugs. Options for “unfit” patients and elderly as well as in second-line setting are discussed. In Chap. 22 non-TCC tumors: Diagnosis and treatment is discussed by Dr. Abol-Enein. He focuses mainly on the squamous cell and adenocarcinoma of the bladder.

We hope that this brief synopsis of the topics covered in each chapter will encourage the readers to use this book for a general read on bladder cancer and as a reference guide for specific molecular and clinical aspects of bladder cancer. We again thank the authors for contributing to this project. We thank our Mr. Michael Koy, production editor at Springer and Spi Editorial Department, India for helping us in the publication of this book. We would like to thank Brian Halm of Springer for helping us with the publication of this book.

 

Information from other sources on Actos and Bladder Cancer

Abstract Bladder cancer (BC) is a worldwide health problem. In 2006 in Europe, there were an estimated 104,400 incident cases of BC diagnosed (82,800 in men and 21,600 in women) that represent a 6.6% of the total cancers in men and 2.1% in women.Tobacco use is a major preventable cause of death, and especially involved with BC carcinogenesis. Tobacco smoking is the most well-established risk factor for BC, causing around 50%-65% of male cases and 20%-30% of female cases.

Occupational exposure has been considered the second most important risk factor for BC. Work related cases account for a 20%-25% of all BC cases in several series.

In addition, chronic urinary tract infection had been related to BC, particularly, with invasive squamous cell carcinoma. Bladder schistosomiasis has particularly- been considered by the international agency for research on cancer (IARC) as a definitive cause or urinary BC with an associated fivefold risk.

 

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Posted in Cancer from Asbestos | Tagged , |

Actos and Bladder Cancer Process

By admin | Published January 25, 2012

Actos and Bladder Cancer : This is what is usually called a “false-positive” test result. The test was positive in a case where it seems that it should have been negative. Any medical test has a cer­tain false-positive rate (usually very low). The problem with a false-positive result with urine cytology is that there is no way to guarantee the absence of cancer. It is always possible that the cancer is there, but we have not been able to find it yet. Sometimes it can hide in places such as the ureters or kidney where we cannot see as well. Other times, especially with carcinoma in situ, the diseased areas look normal through the cysto- scope but actually harbor serious disease. Because of this, one should never ignore a positive cytology result. Close to 80% of patients with a positive cytology but a negative evaluation will eventually be found to have a urologic malignancy.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

The current recommendation for patients with a posi­tive urine cytology and a negative initial evaluation is to repeat the urine cytology 6 to 8 weeks later. Those patients with a negative cytology on the follow-up test do not need further evaluation. If the follow-up cytol­ogy is positive, however, careful evaluation should be undertaken, as most of these patients will eventually be found to have a malignancy. Your urologist may rec­ommend multiple small biopsies of the bladder to look for carcinoma in situ, a condition that is often associ­ated with positive cytology.

Although cytology has long been the gold standard for bladder cancer screening, including monitoring for recur­rences, it is far from perfect (see Question 33), and there is great interest in finding an even better test. Currently, at least four other markers are approved by the Food and Drug Administration (FDA), although none of them are clearly better than cytology. In addition to these four, many new tests are being developed. The four listed here are those that are currently available to patients. If you are considering a radical cystec­tomy, you want an individual who regularly performs that operation. A radical cystectomy is a complicated, time-consuming procedure that some urologists rarely or never perform. The old dictum “practice makes perfect” certainly applies here. Furthermore, if you are interested in the neobladder option for reconstruction of your urinary tract, you should make sure that the urologist is comfortable with that portion of the oper­ation. The neobladder adds complexity to the proce­dure for the surgeon, and not all urologists are well trained in this area. The urologist should know his or her own complication rate for the procedure and not just quote widely published rates for other surgeons. He or she should be comfortable and willing to discuss these rates with you.

Information from other sources on Actos and Bladder Cancer

Cancer can be a frightening word and disease no matter how you look at it. You want a physician who understands your fears and concerns and who is willing to take the time to help you make your management decisions. There is no good measure for this, but trust your instincts at your first meeting with a new doctor. Sometimes you may feel that it is necessary to get a second opinion. You may have concerns about the treatment recommendations or may worry that there are other options that have not been presented. If you ever feel that you have not received enough informa­tion or that you are uncomfortable with the treatment recommendations from your urologist and/or oncolo­gist, then it is appropriate to seek a second opinion.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Posted in Cancer from Asbestos | Tagged , |